Back to top
more

Verona Pharma (VRNA)

(Delayed Data from NSDQ)

$15.47 USD

15.47
260,511

+0.16 (1.05%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.47 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.

Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.

Sundeep Ganoria headshot

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024

by Sundeep Ganoria

Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

by Zacks Equity Research

Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.

Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ligand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.

Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 119.2% in Verona Pharma PLC American Depositary Share (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Verona Pharma PLC American Depositary Share (VRNA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $20.91, moving +0.34% from the previous trading session.

Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Verona Pharma PLC American Depositary Share (VRNA) closed at $20.06, marking a -1.43% move from the previous day.

Verona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $19.51, moving -0.46% from the previous trading session.

Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed at $18.85 in the latest trading session, marking a -0.05% move from the prior day.

Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $21.78, moving +1.59% from the previous trading session.

Verona Pharma PLC American Depositary Share (VRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed at $21.43 in the latest trading session, marking a +0.4% move from the prior day.

Verona (VRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.

Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $22.50, moving +0.72% from the previous trading session.

Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $22.05, moving -1.21% from the previous trading session.

Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed at $20.50 in the latest trading session, marking a -1.44% move from the prior day.

Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed at $22.53 in the latest trading session, marking a -0.75% move from the prior day.

Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed at $23.69 in the latest trading session, marking a -0.96% move from the prior day.

Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Verona Pharma PLC American Depositary Share (VRNA) closed at $23.76 in the latest trading session, marking a -1% move from the prior day.

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

by Zacks Equity Research

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

4 Drug Stocks That More Than Doubled This Year

by Zacks Equity Research

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma PLC American Depositary Share (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.